Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPerrone, Clara
dc.contributor.authorPomella, Silvia
dc.contributor.authorCassandri, Matteo
dc.contributor.authorPezzella, Michele
dc.contributor.authorMilano, Giuseppe Maria
dc.contributor.authorColletti, Marta
dc.contributor.authorRoma Castanyer, Josep
dc.contributor.authorGallego Melcón, Soledad
dc.date.accessioned2022-09-09T08:21:14Z
dc.date.available2022-09-09T08:21:14Z
dc.date.issued2022-04-27
dc.identifier.citationPerrone C, Pomella S, Cassandri M, Pezzella M, Milano GM, Colletti M, et al. MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression. Front Oncol. 2022 Apr 27;12:835642.
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/11351/8095
dc.descriptionResistència als fàrmacs; Sarcoma dels teixits tous; Teràpia dirigida
dc.description.sponsorshipThis research was funded by Associazione Italiana per la Ricerca sul Cancro (AIRC) #15312 to RR and #24696 to FM; Italian Ministry of Health (Ricerca Corrente) to BDA, CQ, and RR; AIRC 5xmille #9962 to FL; Italian Ministry of Health (Fondi 5xmille 2021-2022) to RR; Alleanza Contro il Cancro (ACC) Italian Network-Working Group Sarcomas to BDA, RM, and RR; Fondi Ateneo 2019 to FM; MIUR-Italy: Grant to Department of Science, Roma Tre University (Dipartimento di Eccellenza, ARTICOLO 1, COMMI 314—337 LEGGE 232/2016) to MCe and PM.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology;12
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectTumors de parts toves - Tractament
dc.subjectPediatria
dc.subjectProteïnes quinases - Inhibidors
dc.subject.meshRhabdomyosarcoma
dc.subject.mesh/drug therapy
dc.subject.meshPediatrics
dc.subject.meshProtein Kinase Inhibitors
dc.titleMET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fonc.2022.835642
dc.subject.decsrabdomiosarcoma
dc.subject.decs/farmacoterapia
dc.subject.decspediatría
dc.subject.decsinhibidores de proteínas cinasas
dc.relation.publishversionhttps://doi.org/10.3389/fonc.2022.835642
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Perrone C] Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. Department of Science, “Department of Excellence 2018-2022”, University of Rome “Roma Tre”, Rome, Italy. [Pomella S, Pezzella M, Milano GM, Colletti M] Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. [Cassandri M] Department of Hematology and Oncology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy. Department of Radiotherapy, Sapienza University, Rome, Italy. [Roma J, Gallego S] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35574376
dc.identifier.wos000795729000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple